Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 194 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Human Albumin Clear all
Withdrawn Not applicable Interventional

First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy

NCT02061605
View directory record Official record
Conditions
Benign Renal Tumors, Malignant Renal Tumors
Interventions
Laser Tissue Welding Device
Device
Lead sponsor
Laser Tissue Welding, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Sep 5, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

NCT00684021
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 5, 2026, 8:43 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03886506
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
PLX-PAD
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
45 Years to 99 Years
U.S. locations
2
States / cities
Clifton, New Jersey • Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 5, 2026, 8:43 AM EDT
Completed Early Phase 1 Interventional

u-STOP LVAD Bleed: Utilization of Umbilical Cord Lining Stem Cells (ULSCs) To Prevent Left Ventricular Assist Device (LVAD) Associated Angiodysplastic Bleeding

NCT04811261
View directory record Official record
Conditions
Angiodysplastic Bleeding
Interventions
Intravenous Infusion of UCLSCs
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 5, 2026, 8:43 AM EDT
Terminated Phase 4 Interventional Results available

Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis

NCT00570960
View directory record Official record
Conditions
Spontaneous Bacterial Peritonitis
Interventions
Dextran 70, human albumin
Drug · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 5, 2026, 8:43 AM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 5, 2026, 8:43 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Subarachnoid Hemorrhage With Human Albumin

NCT00283400
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
25% human albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 79 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Hershey, Pennsylvania • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Sep 5, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)

NCT03818737
View directory record Official record
Conditions
Osteoarthritis
Interventions
Bone Marrow Derived MSCs, Adipose-derived MSCs, Umbilical Cord Tissue (UCT) MSCs, Corticosteroid injection
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
40 Years to 70 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Gulf Breeze, Florida • Atlanta, Georgia • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 5, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

NCT00666263
View directory record Official record
Conditions
Multifocal Motor Neuropathy
Interventions
Immune Globulin Intravenous (human), 10%, 0.25% human albumin solution (Placebo)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Centennial, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 5, 2026, 8:43 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 5, 2026, 8:43 AM EDT
Recruiting Phase 2 Interventional

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

NCT05325632
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
HER-2 pulsed DC1, Trastuzumab, Pertuzumab, Paclitaxel, Resection surgery
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 5, 2026, 8:43 AM EDT
Terminated Phase 1 Interventional

Treatment of Subarachnoid Hemorrhage With Human Albumin

NCT01747408
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Human Albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 5, 2026, 8:43 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Vigil for Participants With Ovarian Cancer

NCT02346747
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms
Interventions
Vigil, Placebo
Biological · Other
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
26
States / cities
Mobile, Alabama • Irvine, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 5, 2026, 8:43 AM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

NCT06052176
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Albumin Infusion
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 5, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT00220740
View directory record Official record
Conditions
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Sep 5, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers

NCT01769573
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RG-HRV16, Placebo
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 5, 2026, 8:43 AM EDT
Withdrawn Phase 2 Interventional

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

NCT03574649
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Nab-paclitaxel, Cisplatin, 5Fluorouracil, Cyclophosphamide, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6301, Aldoxorubicin, Avelumab, ALT-803, haNK, Docetaxel, carboplatin
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 5, 2026, 8:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

hCT-MSCs for COVID19 ARDS

NCT04399889
View directory record Official record
Conditions
COVID, Corona Virus Infection, COVID19
Interventions
Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 5, 2026, 8:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reverse Cholesterol Transport (RCT) Study

NCT01031758
View directory record Official record
Conditions
Healthy
Interventions
3H-Cholesterol
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 5, 2026, 8:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

NCT00140140
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer
Interventions
ABI-007, vinorelbine, Trastuzumab, G-CSF
Drug · Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 5, 2026, 8:43 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Pathophysiology of Orthostatic Intolerance

NCT00608725
View directory record Official record
Conditions
Tachycardia, Postural Orthostatic Tachycardia Syndrome
Interventions
DAXOR, QSweat, Intrinsic Heart Rate
Radiation · Procedure · Drug
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 80 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 5, 2026, 8:43 AM EDT
Terminated Phase 4 Interventional Results available

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

NCT01531803
View directory record Official record
Conditions
Hypovolemia
Interventions
Kedbumin 25%, Normal Saline Solution
Drug
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
Up to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Louisville, Kentucky • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 5, 2026, 8:43 AM EDT
Completed Phase 1Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.

NCT03265808
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
allogeneic human mesenchymal stem cells (allo-hMSCs), Placebo
Drug
Lead sponsor
Ihsan M Salloum, MD, MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 5, 2026, 8:43 AM EDT
Terminated Phase 4 Interventional Results available

Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients

NCT04216784
View directory record Official record
Conditions
Cirrhosis, Liver, Volume Overload, Fluid Overload
Interventions
Furosemide Injection, Albumin Human
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 5, 2026, 8:43 AM EDT